Mandarin Capital Triples Investment In Italian Pharma Co.

Law360, New York (February 27, 2012, 7:34 PM EST) -- Chinese private equity firm Mandarin Capital Partners has reportedly tripled its investment in a Milan-based pharmaceutical company after selling part of its majority stake to Italian firm Clessidra SGR SPA.

The deal, which breaks records for a China-based private equity firm, gives Clessidra a 30 percent share in Euticals SPA, a company now valued at $669 million, according to reports from U.K. news site The Alternative Assets Network.

Mandarin Capital, the world’s largest Sino-European private equity fund, retains a 24 percent stake in the company and...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.